Federal Register / Vol. 73, No. 174 / Monday, September 8, 2008 / Notices 52057 

similar alkyltransferase inactivator, O6- 

(4-bromothenyl) guanine is in clinical 

trials in the UK. 

This technology is directed to the 

discovery of a new class of potent 

alkyltransferase inactivators, 2-aminoO4-benzylpteridine derivatives targeted 

for use in cancer treatment in 

combination with chemotherapeutic 

agents such as 1, 3-bis (2-chloroethyl)- 

1-nitrosurea (BCNU) or temozolomide. 

The derivatives of the present invention 

inactivate the O6-alkylguanine-DNAalkyltransferase repair protein and thus 

enhance activity of such 

chemotherapeutic agents. Some of the 

derivatives are water soluble and 

possess tumor cell selectivity in 

particular by inactivating 

alkyltransferase in tumor cells that 

overexpress folic acid receptors. The 2- 

amino-O4-benzylpteridine derivatives 

represent a promising new class of 

alkyltransferase inactivator with 

representatives that may be great 

candidates as chemotherapy adjuvants. 

Applications and Modality: 

• New small molecules as 

alkyltransferase inactivators based on 2- 

amino-O4-benzylpteridine compounds. 

• Promising candidates as 

chemotherapy adjuvants for the 

treatment of cancer. 

• Therapeutic application for drug 

resistant tumors where acquired 

resistance is caused by O6-alkylguanineDNA alkyltransferase. 

Market: 

• 600,000 deaths from cancer related 

diseases estimated in 2006. 

• This technology involving small 

molecule therapeutics for the treatment 

of several cancers has a potential market 

of several billion U.S. dollars. 

Development Status: The technology 

is currently in the pre-clinical stage of 

development. 

Inventors: Robert C. Moschel (NCI) et 

al. 

Publication: ME Nelson, NA 

Loktionova, AE Pegg, RC Moschel. 2- 

amino-O4-benzylpteridine derivatives: 

Potent inactivators of O6-alkylguanineDNA alkyltransferase. J Med Chem. 

2004 Jul 15;47(15):3887–3891. 

Patent Status: 

• U.S. Patent Application No. 10/ 

585,566 filed 29 Aug 2006, claiming 

priority to 06 Jan 2004 (HHS Reference 

No. E–274–2003/0–US–03). 

• Foreign equivalents 

Licensing Status: Available for 

exclusive or non-exclusive licensing. 

Licensing Contact: Adaku 

Nwachukwu, J.D.; 301–435–5560; 

madua@mail.nih.gov. 

Dated: August 26, 2008. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E8–20651 Filed 9–5–08; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health & Human 

Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel EARDA. 

Date: October 3, 2008. 

Time: 9 a.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6100 

Executive Boulevard, 4B01 CRMC, Rockville, 

MD 20852. 

Contact Person: Michele C. HindiAlexander, PhD, Division of Scientific 

Review, National Institutes of Health, Eunice 

Kennedy Shriver National Institute for Child 

Health & Development, 1600 Executive 

Boulevard, 5B01, Bethesda, MD 20812–7510, 

(301) 435–8382, hindialm@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS) 

Dated: August 28, 2008. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E8–20644 Filed 9–5–08; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health & Human 

Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel; The Role of Human 

Milk in Infant Nutrition and Health. 

Date: October 7, 2008. 

Time: 2 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6100 

Executive Boulevard, 5B01, Rockville, MD 

20852 (Telephone Conference Call). 

Contact Person: Rita Anand, PhD, 

Scientific Review Administrator, Division of 

Scientific Review, National Institute of Child 

Health and Human Development, NIH, 6100 

Executive Blvd, Room 5B01, Bethesda, MD 

20892, (301) 496–1487, 

anandr@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS) 

Dated: August 28, 2008. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E8–20646 Filed 9–5–08; 8:45 am] 

BILLING CODE 4140–01–P 

mstockstill on PROD1PC66 with NOTICES